Briefcase Email Alerts Downloads Snapshot RSS Email Printed Materials Print this page

Achieve

Press Releases


 
Press Releases
  Date Title and Summary View
Mar 4, 2009
CARLSBAD, Calif., and CAMBRIDGE, Mass., March 4, 2009 – Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) announced today that Regulus has raised $20 million in a Series A preferred equity financing that further strengthens its balance sheet. Alnylam and Isis w...
Nov 30, 2008
CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)– Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in the journal&n...
Nov 6, 2008
CAMBRIDGE, Mass. & CARLSBAD, Calif.–(BUSINESS WIRE)– Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research findings in the ...
Sep 4, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., September 4, 2008 – Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and the companies’ joint venture Regulus Therapeutics LLC, announced today that the United States Patent and Trademark Office (USPTO) has granted notices of...
Sep 3, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., September 3, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the appointment of Stelios Papadopo...
Aug 19, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., August 19, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the publication of new research in th...
Aug 4, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., August 4, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA-based therapeutics, announced today the appointment of Garry Menzel, Ph.D....
Jun 24, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., June 24, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA (miRNA) therapeutics, announced today that it has been named to the annual ...
May 6, 2008
CAMBRIDGE, Mass. and CARLSBAD, Calif., May 6, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA (miRNA) therapeutics, announced today that it has obtained exclusive rights from Stanford U...
Apr 17, 2008
LONDON, United Kingdom, PHILADELPHIA, Penn. and CARLSBAD, Calif., April 17, 2008 – GlaxoSmithKline (GSK) and Regulus Therapeutics LLC (Regulus) today announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowe...
Page: FirstPrevious ...
21
NextLast
= add release to Briefcase